ArticlePediatric nephrology (Berlin, Germany)2026
Tailoring HLA antibody monitoring post-transplantation.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte antigen (HLA) donor-specific antibodies (DSA) are among the most important determinants of late allograft loss after kidney transplantation. However, no uniform monitoring strategy has been validated in pediatric recipients. This educational review recommends that post-transplant HLA antibody monitoring in children should be tailored to the individual patient's immunological risk profile rather than applied as a fixed schedule. Pediatric recipients face a heterogeneous risk landscape due to prolonged allograft exposure, high age-specific risk of nonadherence during adolescence, and the influence of the chosen immunosuppressive regimen, which demands a differentiated approach. Drawing on current international consensus documents, multicenter registry data, and emerging pediatric cohort studies, this review examines the scientific basis of HLA antibody-mediated injury, the available diagnostic tools, and the supporting evidence for risk-adapted monitoring intervals, individualized trigger-based testing, and interpretation of test results as mean fluorescence intensity (MFI) in a clinical context. We give special attention to adolescence and nonadherence as high-risk categories warranting intensified surveillance. We aim to provide a practical framework for tailored personalized HLA antibody monitoring that is applicable in the daily care of pediatric kidney transplant recipients.
Indexed as
Identifiers
42635784What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.